Although the patho-physiologic implications of the S100 proteins in cancer still require further clarification, the description of their differential occurrence in a large group of breast cancer patients, at proteomic levels, is a further important step promoting advancement of scientific knowledge for biomarker application in clinical practice. The gene discussed is S100A1; the disease is breast carcinoma.